

Edgar Filing: PFIZER INC - Form 8-K

PFIZER INC  
Form 8-K  
April 19, 2005

=====

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report: April 19, 2005  
Date of earliest event reported: April 18, 2005

PFIZER INC.  
(Exact name of registrant as specified in its charter)

|  |                                       |   |
|--|---------------------------------------|---|
| Delaware<br>(State or other<br>jurisdiction of<br>incorporation) | 1-3619<br>(Commission File<br>Number) | 13-5315170<br>(I.R.S. Employer<br>Identification No.) |
|--|---------------------------------------|---|

|  |                     |
|--|---------------------|
| 235 East 42nd Street<br>New York, New York<br>(Address of principal executive offices) | 10017<br>(Zip Code) |
|--|---------------------|

Registrant's telephone number, including area code:  
(212) 573-2323

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

=====

Item 2.02 Results of Operations and Financial Condition

On April 19, 2005, Pfizer Inc. (the "Company" or "Pfizer") issued a press release announcing its financial results for the first quarter of 2005. The information contained in the press release is deemed to be "filed" under the Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press release is incorporated herein by reference.

## Edgar Filing: PFIZER INC - Form 8-K

### Item 2.06 Material Impairments

On April 18, 2005, the Company determined that certain intangible assets relating to Bextra, one of our selective Cox-2 inhibitor pain relievers, have become impaired due to our decision, announced on April 7, 2005, to suspend the sales of Bextra. The Company recorded certain charges totaling \$1.213 billion (\$766 million, net of tax) in the first quarter of 2005. These pre-tax charges included \$1.145 billion relating to the impairment of Bextra's intangible assets for developed technology rights, \$10 million for the write-off of machinery and equipment, \$56 million in write-offs of inventory, and \$2 million relating to the costs of administering the suspension of sales.

### Item 9.01 Financial Statements and Exhibits

#### (c) Exhibits

Exhibit 99 - Press Release of Pfizer Inc. dated April 19, 2005, reporting Pfizer's financial results for the first quarter of 2005. Exhibit 99 is deemed to be "filed" under the Securities Exchange Act of 1934 in this Current Report on Form 8-K.

#### SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

-----  
Margaret M. Foran  
Title: Vice President-Corporate  
Governance and Secretary

Dated: April 19, 2005

#### EXHIBIT INDEX

| Exhibit No. | Description  |
|-------------|--|
| 99          | Press Release of Pfizer Inc. dated April 19, 2005, reporting Pfizer's financial results for the first quarter of 2005. |